Alpha-Lipoic Acid for Neuropathy: Dose and Timeline

Why alpha-lipoic acid gets the attention

If you line up every ingredient marketed for nerve health and sort them by the weight of human evidence behind them, one name sits at the top: alpha-lipoic acid, usually shortened to ALA. It is a naturally occurring compound your cells use in energy metabolism, and it works as an antioxidant that is unusual in being able to operate in both watery and fatty parts of a cell. That dual solubility is part of why researchers took an interest in it for nerves, where oxidative stress driven by high blood sugar is thought to play a role in damage over time.

Importantly, ALA is not a painkiller and it is not a cure. What the research points to is something narrower and more honest: in the right people, at the right dose, over enough weeks, it can modestly ease the day-to-day symptoms of diabetic peripheral neuropathy - the burning, prickling, tingling and numbness that often show up first in the feet. That is a real but limited claim, and it is worth understanding exactly how the evidence got there before you decide whether it is worth your money.

The trial everyone cites: SYDNEY 2

The single most-quoted piece of evidence is the SYDNEY 2 trial, a randomized, placebo-controlled study that tested oral alpha-lipoic acid in people with diabetic neuropathy. Participants took ALA daily for roughly five weeks, and researchers tracked symptom scores that combine pain, burning, numbness and prickling into one number. In the group taking 600 mg per day, the total symptom score improved by around 51 percent, compared with about 37 percent in the placebo group.

Two things are worth pulling out of those numbers. First, the placebo response was large - more than a third of the benefit showed up even in people taking a dummy capsule, which is a useful reminder that nerve symptoms fluctuate and that expectation matters. Second, the gap between ALA and placebo was real but measured, not miraculous. ALA came out ahead, and it did so at a tolerable dose. The trial also tested higher doses of 1,200 mg and 1,800 mg per day, and those did not deliver clearly better symptom relief - they simply produced more stomach-related side effects. That is the origin of the 600 mg standard: it is the dose that captured most of the benefit without buying extra trouble.

How the dose options compare

Daily oral dose	What the research suggests
600 mg	The studied standard; most of the symptom benefit with good tolerability
1,200 mg	No clear extra benefit over 600 mg; more digestive upset reported
1,800 mg	Still no clear added benefit; highest rate of side effects
Below 600 mg	Less studied for symptoms; harder to compare with trial results

Why 600 mg became the reference point

Supplement labels love to imply that more is better, but ALA is a clean example of why that logic fails. Once the 600 mg mark is reached, the extra antioxidant capacity does not translate into extra symptom relief in the trials - the curve flattens. Meanwhile the most common complaint at higher doses is nausea and general stomach discomfort, which is exactly the sort of nuisance that makes people quit before they have given a supplement a fair run. So 600 mg per day is not a magic number; it is the point where the evidence and the tolerability lines cross most favourably. If a product buries ALA inside a proprietary blend, the practical problem is that you cannot tell whether you are anywhere near that 600 mg figure.

Oral versus IV: what changed

Some of the earliest positive research on ALA used the intravenous form, delivered in a clinic over a few weeks. IV bypasses the gut and gets more of the compound into circulation quickly, which made it a convenient way for researchers to test whether ALA did anything at all. The answer was encouraging, but IV infusions are impractical for ordinary daily use - nobody wants to sit in a clinic for a supplement.

The value of trials like SYDNEY 2 is that they showed the oral route can also produce a measurable symptom benefit, just at a more modest scale and over a slightly longer window. For the vast majority of people, oral 600 mg per day is the realistic option, and it is the one to plan around. IV ALA is a medical decision that belongs entirely with a clinician, not something to chase on your own.

A realistic timeline: think in weeks

The most common mistake people make with alpha-lipoic acid is judging it too soon. It is not an analgesic that quietens a nerve within an hour, and expecting overnight relief is a recipe for disappointment. In the trials, symptom scores drifted downward over the course of weeks, not days. A sensible personal plan looks like this: take 600 mg per day consistently, keep a short daily note of your worst symptom on a simple scale, and do not draw any conclusions for at least four weeks. Many people give it the full eight weeks of the studied window before deciding either way.

Keeping that written log is more useful than it sounds. Nerve symptoms wax and wane with sleep, stress, blood sugar and activity, so memory alone is a poor judge. A few seconds of scoring each evening gives you an honest trend line, which is exactly what a doctor will want to see if you discuss it at your next appointment.

Does it help beyond diabetes?

This is where honesty matters most. Almost all of the strong ALA evidence comes from diabetic peripheral neuropathy specifically. Its usefulness for nerve symptoms from other causes - chemotherapy, alcohol, compression injuries, or the frustrating cases where no cause is ever found - is far less studied, and the results that do exist are mixed or preliminary. That does not mean ALA is useless outside diabetes; it means we simply do not have the same confidence. If your tingling or numbness is not clearly tied to blood sugar, the priority is identifying the underlying cause with a clinician, because the right fix depends entirely on what is driving the symptoms.

How ALA fits alongside other nutrients

ALA is often paired with benfotiamine, a fat-soluble form of vitamin B1, because the two act on different parts of the same glucose-driven damage pathway. That mechanistic pairing is one reason multi-ingredient nerve formulas frequently list both. The catch, again, is dosing transparency: a formula can name a well-studied ingredient without disclosing whether it contains a research-grade amount. When you compare products, a clearly stated 600 mg of ALA is worth far more than a long ingredient list with a single combined blend weight.

What happens to alpha-lipoic acid over four years, not four weeks

Most of the positive alpha-lipoic acid data comes from trials lasting five weeks to six months, which is a short window for a condition that develops over decades. The exception is the NATHAN 1 trial, which randomised people with mild-to-moderate diabetic polyneuropathy to 600 mg a day of oral ALA or placebo for four years. The primary composite endpoint was not met. Some individual measures of nerve function improved and the treatment was well tolerated, but the headline result was neutral — and that is the single most important piece of context for anyone being sold ALA as a long-term nerve rebuilder.

The picture tightened again with the 2024 Cochrane review of alpha-lipoic acid for diabetic peripheral neuropathy, which graded how certain the evidence is rather than simply counting positive studies. Short-term symptom relief is the claim with the most support behind it; changing the course of the disease is not. Read alongside the SYDNEY 2 trial, the fair summary is this: ALA takes the edge off symptoms for some people over weeks to months, and it has not been shown to change where the neuropathy ends up. That gap between "helps how it feels" and "changes what happens" is exactly the overclaim covered in our piece on nerve-health myths the evidence does not support.

Dose, form and what to expect week by week

The oral dose used across the symptomatic trials is 600 mg a day, usually taken on an empty stomach because food reduces absorption. Higher doses of 1,200 and 1,800 mg were tested in SYDNEY 2 and did not perform better than 600 mg — they mainly produced more nausea. Expect nothing in week one. Where benefit appears, it typically shows up between weeks three and five and then plateaus. If twelve weeks at a proper dose has produced nothing noticeable, more time at the same dose is unlikely to change that.

Two practical cautions. ALA can lower blood glucose, so if you take insulin or a sulfonylurea, any dose change belongs with your prescriber. And because ALA is one of a small handful of nerve ingredients with any randomised data at all, it gets used as the credibility anchor in mixed formulas — which only means something if the label shows you a real 600 mg. Our survey of nerve-health supplements sets out how the whole shelf compares once you grade the evidence rather than the marketing. The other nutrient in that small evidence club, benfotiamine, has a similar profile: genuine trial data, modest effects, and frequently under-dosed in retail products.

Frequently asked questions